STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States, Europe, the Middle East, Asia, Australia, South Africa, and Central and South America. The company operates in two segments, Dermatology Recurring Procedures and Dermatology Procedures Equipment. Its products include XTRAC excimer laser and VTRAC lamp systems that are used for the treatment of psoriasis, vitiligo, atopic dermatitis, eczema, and other skin disorders. The company distributes its products internationally through distributors, and domestically directly to physicians. The company was formerly known as MELA Sciences, Inc and changed its name to STRATA Skin Sciences, Inc. in January 2016. STRATA Skin Sciences, Inc. was incorporated in 1989 and is based in Horsham, Pennsylvania.
IPO Year: 2005
Exchange: NASDAQ
Website: strataskinsciences.com
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
Study published in Journal of Cosmetic and Laser Therapy highlights the TheraClear®X photopneumatic device as an effective treatment option, either as monotherapy or in combination with topical or oral treatments, for patients with mild-moderate acne HORSHAM, Pa., July 17, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the publication of a clinical study titled, "Advancing precision acne therapy using a photopneumatic device," in the July 11, 2024 issue of the Journal of Cosmetic and
HORSHAM, Penn., July 11, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces preliminary total revenue in the range of $8.0 million - $8.4 million for the second quarter of 2024. Consistent with the Company's stated plans of realigning its devices and removing them from underperforming account, the domestic installed base of XTRAC® devices declined from 907 at the end of the first quarter of 2024 to 881 at the end of the second quarter of 2024. The domestic installed base of TheraClear®X d
HORSHAM, Penn., June 12, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the availability of two virtual webinars that discuss the benefits of using its XTRAC® excimer device for the treatment of psoriasis, vitiligo, and eczema and its TheraClear®X photopneumatic device for the treatment of mild to moderate acne. Each webinar is hosted by a leading dermatologist who uses each respective device frequently in his practice and provides an overview of each device, how they use it, and what
HORSHAM, Pa., June 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announces the publication of a clinical study titled, " A 7-Week Open-Label Trial Evaluating the Safety and Efficacy of TheraClear®X for Mitigating Mild-to-Moderate Acne in Healthy Adolescents and Young Adults," in the June 2024 issue of the Journal of Clinical and Aesthetic Dermatology (JCAD). The study was conducted by Dr. Glynis Ablon, a board-certified dermatologist and Associate Clinical Professor UCLA, with 28 yea
HORSHAM, Penn., June 04, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its participation in two dermatology conferences in the month of June. On June 1, STRATA has participated in the inaugural Schweiger Symposium at the Jacob Javits Center in New York City. The Symposium brought together dermatology providers and leaders from multiple states for a day of presentations and professional development sessions and was headed by Dr. Eric Schweiger and the Schweiger Dermatology Group lead
HORSHAM, Penn., May 15, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights Revenue in the first quarter of 2024 was $6.8 million (-11% YOY) vs. $7.6 million in the first quarter of 2023 Global net recurring revenue in the first quarter of 2024 was $4.7 million (-10% YOY) vs. $5.2 million in the first quarter of 2023, and was negatively impacted by deferred billingsGr
HORSHAM, Pa., May 14, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its installed base of TheraClear®X devices surpassed 100 at the end of the first quarter of 2024. As Strata is focused on expanding its TheraClear®X placements within existing XTRAC® partner clinics, a number of the device placements are with private equity-backed dermatology clinics, including the California Skin Institute and Aqua Dermatology, and other strategic accounts, including Pennsylvania Dermatology Partne
HORSHAM, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that Dr. Dolev Rafaeli, President and Chief Executive Officer, and Christopher Lesovitz, Chief Financial Officer, will participate in the Benchmark Healthcare House Call Virtual 1x1 Investor Conference being held on May 21 – 22, 2024. To register, please visit the event page on Benchmark's website: https://www.benchmarkcompany.com/4th-annual-healthcare-house-call-conference/ Dr. Rafaeli and Mr. Lesovitz will be ava
HORSHAM, Penn., May 08, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2024 financial results on Wednesday, May 15, 2024 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Wednesday, May 15, 2024 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested parties withi
HORSHAM, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the placement of six XTRAC® devices with dermatology clinics in the first quarter of 2024 that are considered "comebacks." Comebacks are excimer placements with dermatology clinics that were previously active in the Company's partner program, then terminated their relationship with the Company at some point in the past but have now decided to return to STRATA under the partner program. Among these comebacks are Hen
8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
424B5 - STRATA Skin Sciences, Inc. (0001051514) (Filer)
8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
10-Q - STRATA Skin Sciences, Inc. (0001051514) (Filer)
8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
10-K/A - STRATA Skin Sciences, Inc. (0001051514) (Filer)
8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
8-K - STRATA Skin Sciences, Inc. (0001051514) (Filer)
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
3 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
3 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
3 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
4 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
3 - STRATA Skin Sciences, Inc. (0001051514) (Issuer)
HORSHAM, Penn., May 15, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights Revenue in the first quarter of 2024 was $6.8 million (-11% YOY) vs. $7.6 million in the first quarter of 2023 Global net recurring revenue in the first quarter of 2024 was $4.7 million (-10% YOY) vs. $5.2 million in the first quarter of 2023, and was negatively impacted by deferred billingsGr
HORSHAM, Penn., May 08, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces that it will report first quarter 2024 financial results on Wednesday, May 15, 2024 after the market close. STRATA management will host a conference call at 4:30 p.m. ET on Wednesday, May 15, 2024 to review financial results and provide an update on corporate developments. Following management's formal remarks, there will be a question-and-answer session. To listen to the conference call, interested parties withi
HORSHAM, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN) ("STRATA" or "the Company"), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the fourth quarter and full-year ended December 31, 2023. Fourth Quarter and Full-Year 2023 and Recent Business Highlights: Revenue in the fourth quarter of 2023 was $8.7 million Global recurring revenue was $5.6 millionGross domestic recurring billings were $5.3 million Revenue for the full-year 2023 was $33.4 million Global recurring revenue was $21.5 millionGross domestic recurring b
HORSHAM, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it plans to release its fourth quarter and full-year 2023 financial results on Wednesday, March 27, 2024. Management will hold a conference call to review the financial results and provide a corporate update at 4:30 PM ET on the same day. Wednesday, March 27, 2024, 4:30 PM ETDomestic: 877-269-7756International: 201-689-7817Conference ID: 13744189Webcast: STRATA Skin Sciences Earnings Webcast After the li
HORSHAM, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the third quarter ended September 30, 2023. Third Quarter 2023 and Recent Business Highlights: Total Revenues were $8.9 million compared to $9.4 million for the third quarter of 2022, a total decrease of 6.0%.Non-GAAP EBITDA improved to $1.0 million compared to $0.6 million for the third quarter of 2022.Dr. Dolev Rafaeli, named new Vice-Chairman, President and CEO, effective October 31, 2023. "I am pleased to have
HORSHAM, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced it plans to release its third quarter 2023 financial results on Tuesday, November 14, 2023. Management will hold a conference call to review the financial results and provide a corporate update at 4:30 PM ET on the same day. Tuesday, November 14, 2023, 4:30 PM ET Domestic: 877-269-7756 International: 201-689-7817 Conference ID: 13741439 Webcast: STRATA Skin Sciences Earnings Webcast After the live webcast, the event will be archived
HORSHAM, Pa., Aug. 09, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the second quarter ended June 30, 2023. Second Quarter 2023 and Recent Business Highlights: Revenues in the second quarter of 2023 were $8.3 million, compared to $9.1 million for the second quarter of 2022.Secured up to an additional $12 million financing with MidCap Financial.Placed 73 TheraClear®X devices as of June 30, 2023. "Throughout the second quarter, we achieved significant operational milestones, includ
HORSHAM, Pa., July 28, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its second quarter 2023 financial results on Wednesday, August 9, 2023. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 PM ET on the same day. Wednesday, August 9, 2023, 4:30 PM ETDomestic: 877-269-7756International: 201-689-7817Conference ID: 13739272Webcast: STRATA Skin Sciences Earnings Webcast After the live webcast, the event will be arc
Achieved revenue of $7.6 million for the first quarter 2023 Company to host conference call and webcast today, May 15, 2023, at 4:30 PM ET HORSHAM, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 and Recent Business Highlights: Revenue in the first quarter of 2023 was $7.6, compared to $7.0 million for the first quarter of 2022Officially launched TheraClear®X device in January 202358 TheraClearX devices in the
HORSHAM, Pa., May 02, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced that it plans to release its first quarter 2023 financial results on Monday, May 15, 2023. Management will hold a conference call to review the financial results and provide a corporate update starting at 4:30 PM ET on the same day. Monday, May 15, 2023, 4:30 PM ETDomestic: 877-269-7756International: 201-689-7817Conference ID: 13738266Webcast: STRATA Skin Sciences Earnings Webcast After the live webcast, the event will be archived for fu
SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)
SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)
SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)
SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)
SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)
SC 13G - STRATA Skin Sciences, Inc. (0001051514) (Subject)
SC 13G/A - STRATA Skin Sciences, Inc. (0001051514) (Subject)
Study published in Journal of Cosmetic and Laser Therapy highlights the TheraClear®X photopneumatic device as an effective treatment option, either as monotherapy or in combination with topical or oral treatments, for patients with mild-moderate acne HORSHAM, Pa., July 17, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the publication of a clinical study titled, "Advancing precision acne therapy using a photopneumatic device," in the July 11, 2024 issue of the Journal of Cosmetic and La
STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces preliminary total revenue in the range of $8.0 million - $8.4 million for the second quarter of 2024. Consistent with the Company's stated plans of realigning its devices and removing them from underperforming account, the domestic installed base of XTRAC® devices declined from 907 at the end of the first quarter of 2024 to 881 at the end of the second quarter of 2024. The domestic installed base of TheraClear®X devices continued to grow, rising from 104 at the end
Gainers Lucy Scientific Discovery (NASDAQ:LSDI) stock moved upwards by 123.5% to $1.14 during Thursday's pre-market session. The market value of their outstanding shares is at $2.0 million. SINTX Techs (NASDAQ:SINT) stock moved upwards by 19.67% to $0.15. The market value of their outstanding shares is at $18.7 million. As per the press release, Q1 earnings came out 3 days ago. Dynatronics (NASDAQ:DYNT) stock increased by 16.7% to $0.51. The market value of their outstanding shares is at $2.7 million. Ontrak (NASDAQ:OTRK) shares moved upwards by 15.99% to $0.31. The company's market cap stands at $14.8 million. The company's, Q1 earnings came out 2 days ago. NovaBay Pharmaceuticals (AME
Gainers SINTX Techs (NASDAQ:SINT) shares increased by 22.2% to $0.16 during Wednesday's after-market session. The company's market cap stands at $19.1 million. As per the news, the Q1 earnings report came out 2 days ago. Petros Pharma (NASDAQ:PTPI) shares rose 12.85% to $0.58. The market value of their outstanding shares is at $4.0 million. Bluejay Diagnostics (NASDAQ:BJDX) shares increased by 10.22% to $0.58. The market value of their outstanding shares is at $1.5 million. INVO Bioscience (NASDAQ:INVO) stock rose 7.47% to $1.15. The market value of their outstanding shares is at $4.3 million. Scorpius Holdings (AMEX:SCPX) shares moved upwards by 7.2% to $0.08. The market value of their
Strata Skin Sciences (NASDAQ:SSKN) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 25 percent decrease over losses of $(0.08) per share from the same period last year. The company reported quarterly sales of $6.754 million which missed the analyst consensus estimate of $6.912 million by 2.28 percent. This is a 10.74 percent decrease over sales of $7.567 million the same period last year.
STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the placement of six XTRAC® devices with dermatology clinics in the first quarter of 2024 that are considered "comebacks." Comebacks are excimer placements with dermatology clinics that were previously active in the Company's partner program, then terminated their relationship with the Company at some point in the past but have now decided to return to STRATA under the partner program. Among these comebacks are Henry Ford Health System in Detroit, Integrated Dermat
Shares of Clever Leaves Holdings Inc. (NASDAQ:CLVR) fell sharply during Monday's session after the company announced that it will voluntarily delist its common shares from the Nasdaq and deregister its Securities to terminate and suspend its reporting obligations. Clever Leaves Holdings shares dipped 60% to $1.6498 on Monday. Here are some other stocks moving in today’s mid-day session. Gainers Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) shares climbed 73% to $25.36 after the company announced it will be acquired by ONO Pharmaceutical for $25.60 per share in cash. Collective Audience, Inc. (NASDAQ:CAUD) gained 50.4% to $0.6002 after the company announced a strategic partne
Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the appointment of Matthew Hill to the position of Chief Financial Officer, effective December 4, 2023. Mr. Hill succeeds Tara Semb, whose departure was announced by the Company on November 9, 2023. "Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the Chief Financial Officer of four publicly-traded healthcare companies," said Charlie Goodwin, President and
HORSHAM, Pa., June 30, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of Dr. Uri Geiger as the Chairman of the Board of Directors. William Humphries will step down as Chairman and continue to serve on the Board, effective July 3, 2023, as he transitions into his role as Chief Executive Officer of Alcami Corporation. "I'm honored to assume the role of Chairman at this pivotal moment in STRATA's growth," said Dr. Uri Geiger, Chairman of STRATA's Board of Directors. "I look forward to levera
HORSHAM, Pa., Feb. 14, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that effective today, Patricia S. Walker M.D., PhD. has been appointed to its Board of Directors. Dr. Walker's vast experience includes more than 35 years as a practicing dermatologist and as a corporate leader in the medical dermatology, medical aesthetics and pharmaceutical industries, executing clinical research and strategic initiatives for a wide range of companies and educational institutions. "We are delighted to welcome Patty to STRAT
HORSHAM, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the quarter ended March 31, 2021. Recent Highlights Total revenue for the first quarter of 2021 was $5.8 million, a decrease of 13.4% as compared to the first quarter of 2020 Recurring revenue for the first quarter of 2021 was $4.7 million, a 17.9% decrease over the first quarter of 2020Gross domestic recurring billings were $4.6 million, a 6.8% decrease over the first quarter 2020 (See Reconciliation of Non-GAAP
HORSHAM, Pa., April 12, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the appointment of William D. Humphries to its Board of Directors. Mr. Humphries' vast experience includes more than 34 years as a key leader in the pharmaceutical industry, contributing strategic direction to a range of high growth public and privately-owned companies. "We are delighted to welcome Bill to STRATA Skin Science's board," said Uri Geiger, Chairman of STRATA's Board of Directors. "His extensive background in the pharmaceu